Affordable Access

Publisher Website

Intraocular pressure–reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma

Authors
Journal
Ophthalmology
0161-6420
Publisher
Elsevier
Publication Date
Volume
111
Issue
3
Identifiers
DOI: 10.1016/j.ophtha.2003.06.007
Keywords
  • Original Article

Abstract

Abstract Objective To demonstrate that the intraocular pressure (IOP)–reducing effect of latanoprost once daily is at least as good as that of timolol twice daily in patients with chronic angle-closure glaucoma (CACG). Design Randomized, double-masked, multicenter 12-week study. Participants In all, 137 patients with unilateral or bilateral CACG were treated with latanoprost, and 138 were treated with timolol. Methods Patients received either latanoprost (9 pm) and a placebo (9 am) or timolol (both 9 am and 9 pm). Intraocular pressure was measured at 9 am and 5 pm at baseline and weeks 2, 6, and 12. Main outcome measures The difference between groups in daily IOP (average of 9 am and 5 pm measures) reduction was the primary outcome. Secondary outcomes included differences between groups in IOP reductions at 9 am and 5 pm, and in proportions of patients reaching specified daily IOP levels. Results Using repeated measures (analysis of covariance: intent to treat), mean changes from baseline in daily IOP levels during 12 weeks were −8.2 mmHg and −5.2 mmHg for latanoprost- and timolol-treated patients, respectively (difference: −3.0 mmHg [95% confidence interval: −4.0, −2.1], P<0.001). Greater reductions in IOP levels at both 9 am and 5 pm were found in latanoprost-treated patients ( P<0.001 for both), and greater proportions of patients receiving latanoprost reached prespecified target daily IOP levels ( P<0.001 for all 3 target levels tested). Both drugs were well tolerated. Conclusion Latanoprost administered once daily provides significantly greater IOP reduction in CACG patients than does timolol instilled twice daily.

There are no comments yet on this publication. Be the first to share your thoughts.